Cargando…

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma

In metastatic melanoma patients, circulating natural killer (NK) cells display phenotypic and functional alterations that appear to correlate with the duration of stage IV disease. Moreover, specific NK cell subsets that exhibit robust tumoricidal functions upon activation by cytokines infiltrate th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Messaoudene, Meriem, Avril, Marie-Françoise, Caignard, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203499/ https://www.ncbi.nlm.nih.gov/pubmed/25340005 http://dx.doi.org/10.4161/onci.28048

Ejemplares similares

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

How melanoma cells inactivate NK cells
por: Pietra, Gabriella, et al.
Publicado: (2012)

New insights into the role of NK cells in cancer immunotherapy
por: Salagianni, Maria, et al.
Publicado: (2012)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens
por: Gameiro, Sofia R, et al.
Publicado: (2014)

Toward the next generation of NK cell-based adoptive cancer immunotherapy
por: Ni, Jing, et al.
Publicado: (2013)

A novel pathway links telomeres to NK-cell activity: Implications for immunotherapy
por: Cherfils-Vicini, Julien, et al.
Publicado: (2014)

When breast cancer cells start to fend the educational process of NK cells off
por: Mamessier, Emilie, et al.
Publicado: (2013)

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
por: Nagato, Toshihiro, et al.
Publicado: (2014)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy?
por: Vacca, Paola, et al.
Publicado: (2013)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
por: Swarbrick, Alexander, et al.
Publicado: (2013)

NK-cell fratricide: Dynamic crosstalk between NK and cancer cells
por: Nakamura, Kyohei, et al.
Publicado: (2013)

“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
por: Janji, Bassam, et al.
Publicado: (2021)

NK cell-released exosomes: Natural nanobullets against tumors
por: Fais, Stefano
Publicado: (2013)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

How to outsmart NK cell tolerance
por: Terszowski, Grzegorz, et al.
Publicado: (2015)

In vivo evidence for dendritic cell lysis by NK cells: Hints on improving cancer vaccines by targeting NK cell activation
por: Ferlazzo, Guido
Publicado: (2012)

NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
por: Frazao, Alexandra, et al.
Publicado: (2019)

NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies
por: Fregni, Giulia, et al.
Publicado: (2012)

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

Tumor microenvironment in NSCLC suppresses NK cells function
por: Cremer, Isabelle, et al.
Publicado: (2012)

Dacarbazine mediates antimelanoma effects via NK cells
por: Hervieu, Alice, et al.
Publicado: (2013)

HMGB1: The metabolic weapon in the arsenal of NK cells
por: Cerwenka, Adelheid, et al.
Publicado: (2016)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Role of the complement system in NK cell-mediated antitumor T-cell responses
por: Janelle, Valérie, et al.
Publicado: (2014)

Linking apoptosis to cancer metabolism: Another missing piece of JuNK
por: Papa, Salvatore, et al.
Publicado: (2016)

Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy
por: Alvarez-Breckenridge, Christopher A., et al.
Publicado: (2013)

Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination
por: Tai, Lee-Hwa, et al.
Publicado: (2013)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages
por: Fregni, Giulia, et al.
Publicado: (2013)

A “vicious cycle” of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?
por: Schmiedel, Benjamin Joachim, et al.
Publicado: (2013)

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression
por: Aspord, Caroline, et al.
Publicado: (2014)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Shock block for improved immunotherapy
por: Rao, Aparna, et al.
Publicado: (2012)

Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors
por: Achour, Abla, et al.
Publicado: (2014)

Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment
por: Schuessler, Andrea, et al.
Publicado: (2014)

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
por: Deng, Liufu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_89tac34kl26br24k8kupi4kka8